Full OptIMMize-1 results show high skin clearance rates with risankizumab in children and teens with psoriasis, sustained through 52 weeks.
News|Videos|September 4, 2025
August's FDA Focus: Approvals and pipeline updates in pediatrics
Author(s)Joshua Fitch, Senior Editor
Fact checked by: Morgan Ebert, Executive Editor
Watch our FDA pipeline news recap for the month for August 2025, as well as a preview of PDUFA dates listed for September.
Advertisement
Advertisement
Welcome to FDA Focus, where we take you back and recap some of the top FDA approvals of the month and provide a look ahead at what to expect in the month to come from the federal agency.
Related to this article
Post hoc data show cariprazine improved both manic and depressive symptoms through 52 weeks in youth aged 10 to 17 years with bipolar I disorder.
Find out the 4 FDA decisions to watch in November 2026 for pediatric care.
Cenobamate sNDAs target PGTC seizures in patients ≥12 years and pediatric focal seizures; phase 3 PGTC data showed a 71.9% median reduction.
FDA approved Lupin's generic of Firdapse for LEMS in patients 6 years and older, but a patent settlement delays US marketing until at least 2035.
A recap of the top pediatric clinical trial results and pipeline data readouts during October 2026.
A recap of the top FDA approvals, regulatory decisions, and pipeline updates affecting pediatric care during October 2026.
In PROGRESS Cohort 2, zilurgisertib reduced total HO volume vs placebo at 24 weeks in children aged 6 to 11 with FOP, with no new HO lesions.
Advertisement
Advertisement